Yahoo · Sep 3, 2026
Sector Update: Healthcare Stocks Edge Higher Late Afternoon
Healthcare stocks were slightly higher late Thursday afternoon, with the NYSE Healthcare Index incre
AP
NASDAQ · APGE
Apogee Therapeutics, Inc.
Healthcare · Biotechnology
$135.07
Up+$0.00 (+0.00%)
Updated Oct 8, 2026, 4:06 AM
SID Score
6.6/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 3.84B
- P/E ratio
- -16.22
- Dividend yield
- 0.00%
- 52-week range
- $35.39 – $135.09
- Volume
- 5.14M
- Avg. volume
- 981.84K
Price performance · APGE
APGE price history
1M range · 0 trading sessions · Daily adjusted prices
APGE does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest APGE news
The latest Smart Investors Daily articles mentioning APGE.
Stock researchCompany · Overview
Company
Market Activity
Research & News
APGE research
Overview
Company profile and research snapshot.
Company profile
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $90.67
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | Truist Securities | Hold | — |
| Aug 12, 2026 | BTIG | Neutral | — |
| Jun 24, 2026 | Stifel | Hold | — |
| Jun 24, 2026 | TD Cowen | Hold | — |
| Jun 24, 2026 | Mizuho | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 3, 2026
ABBV Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell?
AbbVie's Skyrizi, Rinvoq and neuroscience drugs drive growth, but Humira erosion, oncology and Aesthetics remain key headwinds.
Yahoo · Sep 3, 2026
AbbVie Completes Acquisition of Apogee Therapeutics
AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Apogee Therapeutics, Inc. (NASDAQ: APGE). With completion of the acquisition, Apogee is now part of AbbVie. Under the terms of the agreement, Apogee shareholders received $135.11 per share in cash, for a total equity value of approximately $10.9 billion.
Yahoo · Sep 2, 2026
Kymera's KT-621 Has 'Oral Dupixent' Potential, but Valuation Limits Upside, RBC Says
Kymera Therapeutics' (KYMR) KT-621 could validate its "oral Dupixent" potential, but with a roughly
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
